Switch theme
Sign up to access all valuation multiples
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
2019
1
LTM Revenue $2.6M
LTM EBITDA -$0.2M
$3.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ODI Pharma has a last 12-month revenue of $2.6M and a last 12-month EBITDA of -$0.2M.
In the most recent fiscal year, ODI Pharma achieved revenue of $2.2M and an EBITDA of $48K.
ODI Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ODI Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14K | $2.2M | XXX | XXX | XXX |
| Gross Profit | -$10K | -$0.1M | XXX | XXX | XXX |
| Gross Margin | -74% | -3% | XXX | XXX | XXX |
| EBITDA | -$0.7M | $48K | XXX | XXX | XXX |
| EBITDA Margin | -4864% | 2% | XXX | XXX | XXX |
| Net Profit | -$0.7M | -$0.7M | XXX | XXX | XXX |
| Net Margin | -5191% | -31% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ODI Pharma's stock price is SEK 3 (or $0).
ODI Pharma has current market cap of SEK 42.7M (or $4.2M), and EV of SEK 37.3M (or $3.7M).
See ODI Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7M | $4.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ODI Pharma has market cap of $4.2M and EV of $3.7M.
ODI Pharma's trades at 1.4x LTM EV/Revenue multiple, and -22.6x LTM EBITDA.
Analysts estimate ODI Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ODI Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.7M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | -38.8x | XXX | XXX | XXX |
| P/E | -23.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpODI Pharma's NTM/LTM revenue growth is 177%
ODI Pharma's revenue per employee for the last fiscal year averaged $2.2M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, ODI Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ODI Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ODI Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 15880% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -107% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 173% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 19% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ODI Pharma acquired XXX companies to date.
Last acquisition by ODI Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . ODI Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ODI Pharma founded? | ODI Pharma was founded in 2019. |
| Where is ODI Pharma headquartered? | ODI Pharma is headquartered in Sweden. |
| How many employees does ODI Pharma have? | As of today, ODI Pharma has 1 employees. |
| Is ODI Pharma publicy listed? | Yes, ODI Pharma is a public company listed on SAT. |
| What is the stock symbol of ODI Pharma? | ODI Pharma trades under ODI ticker. |
| When did ODI Pharma go public? | ODI Pharma went public in 2020. |
| Who are competitors of ODI Pharma? | Similar companies to ODI Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ODI Pharma? | ODI Pharma's current market cap is $4.2M |
| What is the current revenue of ODI Pharma? | ODI Pharma's last 12-month revenue is $2.6M. |
| What is the current EBITDA of ODI Pharma? | ODI Pharma's last 12-month EBITDA is -$0.2M. |
| What is the current EV/Revenue multiple of ODI Pharma? | Current revenue multiple of ODI Pharma is 1.4x. |
| What is the current EV/EBITDA multiple of ODI Pharma? | Current EBITDA multiple of ODI Pharma is -22.6x. |
| What is the current revenue growth of ODI Pharma? | ODI Pharma revenue growth between 2023 and 2024 was 15880%. |
| Is ODI Pharma profitable? | Yes, ODI Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
